Eli Lilly’s Alzheimer’s OK; GSK picks its mRNA bets; Megaround tally;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleWhen can pharma companies correct online misinformation? FDA explains
The FDA on Monday laid out its latest expectations for how pharma companies can correct misinformation spreading online about their medical products. The draft guidance, which comes in the form of a...
View ArticleLilly bests Novo Nordisk in observational study of GLP-1 drugs
Patients receiving Eli Lilly’s diabetes medicine Mounjaro were “significantly more likely” to achieve clinically meaningful weight loss compared to those on Novo Nordisk’s Ozempic, according to a new...
View ArticleGilead's HIV drug patent battle with CDC continues with government appeal
The US government is appealing a jury’s decision that granted Gilead a major win in a patent fight over the company’s blockbuster HIV treatments Truvada and Descovy. Lawyers for the government last...
View ArticleRoche to reintroduce ocular implant two years after pulling it off the market
Roche plans to reintroduce Susvimo, its ocular implant pulled almost two years ago for manufacturing issues, in the coming weeks. In late 2022, the company’s Genentech unit withdrew the implant after a...
View ArticleAcquired biotech accuses Novartis of letting IL-15 asset 'wither on the vine'
Novartis is being accused of deliberately stalling the development of an acquired IL-15 asset, costing a smaller biotech up to $940 million in milestone payments plus additional damages and costs. The...
View ArticleClik here to view.
SciRhom secures €63M Series A for autoimmune disease program
SciRhom has raised €63 million ($70 million) in a Series A to advance its lead monoclonal antibody program through a first-in-human trial set to start in the second half of the year. The Phase 1 trial...
View ArticleBiovance debuts with €51M to lift up biotech scene in Portugal and southern...
Nearly a decade ago, Ricardo Perdigão Henriques’ colleagues balked at the idea of him leaving Boston to return home to Portugal to build a biotech ecosystem as a VC. “They said, ‘You’re crazy, Ricardo....
View ArticleExclusive: Courier Health raises $16.5M Series A to help biopharma companies...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) As more specialty drugs hit the market, a startup just raised fresh funding to help biopharma companies...
View ArticleHouse speaker plans vote on Biosecure Act as part of China legislation push
House Speaker Mike Johnson (R-LA) on Monday pledged a vote this year on a bill targeting Chinese biotech contractors, providing fresh momentum to the legislation. Johnson listed the Biosecure Act among...
View ArticleClik here to view.
Pfizer CSO Mikael Dolsten to depart after 15 years leading drug giant's R&D
Mikael Dolsten, a longtime leader of drug R&D at one of the world’s biggest pharma giants, will depart his post as chief scientific officer at Pfizer, the company said Tuesday morning. The 15-year...
View ArticleFTC says PBMs ‘exercise vast control’ over healthcare in long-awaited report...
Federal antitrust regulators issued a report describing the PBM industry as highly concentrated among a handful of companies that use their market power to put pressure on clients and competitors, and...
View ArticleClik here to view.
Chinese drugmakers still lag in R&D depth despite outpacing Europeans in new...
China may have outranked Europe for the first time in the number of new medicines it developed through to launch last year. But analysts told Endpoints News that Europe still has the edge when it comes...
View ArticleClik here to view.
Biopharma’s 20 highest-paid CEOs of 2023, earning $20M+ pay packages
The best-paid CEOs of 2023 fall largely into two groups: They’re either running some of the world’s biggest drugmakers, or they were given huge incentive packages in their first year on the job or as...
View ArticleKymera's stock rises after derma investigation expands; Ligand buys Apeiron
Plus, news about AEON Biopharma, Moderna and Mitsubishi Tanabe: Sanofi expands dermatology trials: Kymera Therapeutics said that expanding the Phase 2 hidradenitis suppurativa and atopic dermatitis...
View ArticleClik here to view.
UniQure trumpets mid-stage data for Huntington's disease gene therapy
UniQure on Tuesday released new two-year data on its Huntington’s disease gene therapy called AMT-130, sending its stock $QURE up by more than 50%. Interim results from the Phase 1/2 trials showed nine...
View ArticleIntellia to respond to lawsuit over in vivo therapy patents
Intellia Therapeutics said it will respond to a lawsuit filed Monday in a Delaware federal court alleging it infringed on several of BlueAllele’s patents covering methods for targeted insertion of DNA...
View ArticleZevra to face FDA adcomm in August over previously rejected rare disease drug
The FDA’s recently created Genetic Metabolic Diseases Advisory Committee will meet on Aug. 2 to review Zevra Therapeutics’ arimoclomol as a treatment for the rare and fatal genetic disorder known as...
View ArticleSix big R&D questions for Pfizer as science chief Dolsten exits
The planned exit of longstanding Pfizer Chief Scientific Officer Mikael Dolsten comes at a pivotal moment for the huge drugmaker. The Covid-19 vaccine aura has fully worn off, it’s made a spate of...
View ArticleAmgen shelves early-stage bispecific T cell engager
Amgen has stopped development of a Phase 1 bispecific T cell engager, a type of medicine that is core to its oncology portfolio and for which it has trademarked the BiTE acronym. The California...
View Article